WASHINGTON — The Trump administration is expected to announce the results of the second round of Medicare drug-price negotiations soon.
They’ll be closely watched for two big reasons: Medicare is negotiating the price of the blockbuster diabetes and weight-loss drug semaglutide, sold under the brands Ozempic and Wegovy. And Trump has bragged that he’ll strike better deals than Biden’s team, even as he’s criticized the law and weakened it by exempting or delaying negotiations on certain drugs.
In fact, a few factors could help this administration secure bigger savings than the Biden administration managed in the first round, according to drug pricing experts STAT interviewed. They include the drugs selected for negotiation and the fact that Trump’s team benefits from the experience of Biden’s efforts.
